BRIEF-JP Morgan raises targets on European pharma cos - News

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.
Smartphone Guide
Here's a need-to-know guide to nine devices, based on features, price, network and platform.
Wines for the Holidays
Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES

How Well Do You Know Your Bird?
Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.
A Healthier & Wealthier You
Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

BRIEF-JP Morgan raises targets on European pharma cos

By: AFX | 16 Nov 2009 | 04:31 AM ET

Text Size

Nov 16 (Reuters) - * JP Morgan raises Actelion price target to 73 SFR from 69 SFR * JP Morgan raises Ipsen SA price target to 50 EUR from 49 EUR * JP Morgan raises Merck KGaA price target to 80 EUR from 70 EUR * JP Morgan raises Novo Nordisk price target to 380 dkk from 345 dkk * JP Morgan raises UCB SA price target to 29 EUR from 20 EUR * JP Morgan raises Shire Plc price target to 1,345P from 1,120P (Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Tools: